National Cancer Institute (NCI): Glioblastoma trials

The registry lists 120 Glioblastoma studies with National Cancer Institute (NCI) as lead sponsor. 6 are open to participants now and 57 have results posted.

Phase 1 66Phase 2 70Phase 3 2No phase 8(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent GlioblastomaNot yet recruitingNCT07422363Phase 1
• Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or AstrocytomaRecruitingNCT06860594Phase 1
• Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent GlioblastomaRecruitingNCT06344130Phase 1
• PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN AmplificationsRecruitingNCT06161519Phase 1/2
• Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous TreatmentRecruitingNCT05432804Phase 1/2
• Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma MultiformeRecruitingNCT00083512
• Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent GlioblastomaActive, not recruitingNCT04729959Phase 2Results posted
• Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed GlioblastomaActive, not recruitingNCT04216329Phase 1Results posted
• Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator PhenotypeActive, not recruitingNCT03718767Phase 2Results posted
• Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their CaregiversCompletedNCT03538587Not applicableResults posted
• Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 MutationsActive, not recruitingNCT03212274Phase 2Results posted
• Protein Phosphatase 2A Inhibitor, in Recurrent GlioblastomaCompletedNCT03027388Phase 2Results posted
• Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)TerminatedNCT03018288Phase 2Results posted
• Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent GlioblastomaActive, not recruitingNCT02974621Phase 2Results posted
• Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and GlioblastomaTerminatedNCT02942264Phase 1/2Results posted
• Methoxyamine and Temozolomide in Treating Patients With Recurrent GlioblastomaTerminatedNCT02395692Phase 2Results posted
• Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeActive, not recruitingNCT02152982Phase 2/3Results posted
• TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid TumorsActive, not recruitingNCT02142803Phase 1Results posted
• Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior BevacizumabCompletedNCT01931098Phase 2Results posted
• Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine GliomasCompletedNCT01922076Phase 1Results posted
• TRC105 for Recurrent GlioblastomaTerminatedNCT01778530Phase 2Results posted
• Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT01648348Phase 1/2Results posted
• Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain TumorsCompletedNCT01609790Phase 2Results posted
• Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine GliomasCompletedNCT01514201Phase 1/2Results posted
• CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIIICompletedNCT01454596Phase 1/2Results posted
• Phase I-II Everolimus and Sorafenib in Recurrent High-Grade GliomasCompletedNCT01434602Phase 1/2Results posted
• Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive GlioblastomaCompletedNCT01342757Not applicableResults posted
• Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent GlioblastomaCompletedNCT01266031Phase 1/2Results posted
• RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant GliomaTerminatedNCT01189240Phase 1/2Results posted
• Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive GlioblastomaTerminatedNCT01122901Phase 2Results posted
• Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed GlioblastomaCompletedNCT01062425Phase 2Results posted
• Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant GliomaCompletedNCT01051557Phase 1/2Results posted
• A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade GliomasCompletedNCT00995007Phase 2Results posted
• GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by SurgeryCompletedNCT00980343Phase 2Results posted
• Sunitinib to Treat Recurrent Brain CancerTerminatedNCT00923117Phase 2Results posted
• MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00902577Phase 2Results posted
• Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed GlioblastomaCompletedNCT00884741Phase 3Results posted
• Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00731731Phase 1/2Results posted
• Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard TherapyCompletedNCT00679354Phase 2Results posted
• Tandutinib Plus Bevacizumab to Treat Recurrent Brain TumorsCompletedNCT00667394Phase 2Results posted
• Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma MultiformeCompletedNCT00641706Phase 2Results posted
• Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma MultiformeCompletedNCT00540722Phase 2Results posted
• Sunitinib in Treating Patients With Recurrent Malignant GliomasCompletedNCT00499473Phase 2Results posted
• Pazopanib in Treating Patients With Recurrent GlioblastomaCompletedNCT00459381Phase 2Results posted
• Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma MultiformeCompletedNCT00445588Phase 2Results posted
• O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation TherapyTerminatedNCT00436436Phase 2Results posted
• Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or GliosarcomaCompletedNCT00433381Phase 2Results posted
• Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaCompletedNCT00423735Phase 2Results posted
• Tandutinib in Treating Patients With Recurrent or Progressive GlioblastomaCompletedNCT00379080Phase 1/2Results posted
• VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to TemozolomideCompletedNCT00369590Phase 2Results posted
• Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaCompletedNCT00335764Phase 1/2Results posted
• Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent GlioblastomaCompletedNCT00329719Phase 1/2Results posted
• Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or GliosarcomaCompletedNCT00305864Phase 1/2Results posted
• Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma MultiformeCompletedNCT00238303Phase 2Results posted
• Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma MultiformeTerminatedNCT00112866Phase 2Results posted
• Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant GliomaCompletedNCT00112736Phase 1/2Results posted
• Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System TumorsCompletedNCT00095940Phase 1/2Results posted
• FR901228 in Treating Patients With Recurrent High-Grade GliomasCompletedNCT00085540Phase 1/2Results posted
• Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00085254Phase 1/2Results posted
• A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade GliomasCompletedNCT00045708Phase 1/2Results posted
• Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive MeningiomaCompletedNCT00045110Phase 1/2Results posted
• Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed GliomasCompletedNCT00042991Phase 1/2Results posted
• Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBMCompletedNCT00004146Phase 2Results posted
• Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent GlioblastomaWithdrawnNCT06328036Phase 2
• Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent GlioblastomaSuspendedNCT06325683Phase 2
• Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or GliosarcomaCompletedNCT04817254Phase 2
• A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational BurdenActive, not recruitingNCT04145115Phase 2
• Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade GliomaActive, not recruitingNCT03919071Phase 2
• Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain CancerTerminatedNCT03107780Phase 1
• Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent GlioblastomaCompletedNCT02709226Phase 1
• Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or GliosarcomaCompletedNCT02311920Phase 1
• Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT02227901Phase 1
• Sapanisertib Before and After Surgery in Treating Patients With Recurrent GlioblastomaTerminatedNCT02133183Phase 1
• Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade GliomaCompletedNCT02101905Phase 1
• Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent GlioblastomaCompletedNCT01849146Phase 1
• AZD7451 for Recurrent GliomasCompletedNCT01468324Phase 1
• High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent GliomaTerminatedNCT01378481Phase 1
• AZD8055 for Adults With Recurrent GliomasCompletedNCT01316809Phase 1
• (11C)dLop as a Marker of P-Glycoprotein Function in Patients With GliomasTerminatedNCT01281982
• RO4929097 in Treating Patients With Recurrent Invasive GliomasTerminatedNCT01269411Phase 1
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsCompletedNCT01131234Phase 1
• Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma MultiformeTerminatedNCT01122888Phase 1
• RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant GliomaCompletedNCT01119599Phase 1
• A Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With GliomasWithdrawnNCT01117155
• Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord TumorsCompletedNCT01076530Phase 1
• Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent GlioblastomaCompletedNCT00979862Phase 1
• ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS TumorsCompletedNCT00946335Phase 1
• Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaCompletedNCT00662506Phase 1/2
• Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant GliomaCompletedNCT00650923Phase 1
• Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant GliomaTerminatedNCT00430079Not applicable
• Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or LymphomaCompletedNCT00363272Phase 1
• Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00316849Phase 1
• AZD2171 in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00305656Phase 2
• Vorinostat and Temozolomide in Treating Patients With Malignant GliomasActive, not recruitingNCT00268385Phase 1
• Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain TumorsTerminatedNCT00110032Phase 1
• GW572016 to Treat Recurrent Malignant Brain TumorsCompletedNCT00107003Phase 2
• Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS TumorsCompletedNCT00100880Phase 1
• Sorafenib in Treating Patients With Recurrent or Progressive Malignant GliomaCompletedNCT00093613Phase 1
• Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous TreatmentCompletedNCT00091182Phase 2
• Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma MultiformeTerminatedNCT00075491Phase 2